Leaders in RNA and DNA Testing
Liquid Biopsy Labs Team
Liquid Biopsy Labs – a devoted team passionate about developing groundbreaking cancer testing to help cancer patients, doctors, and facilities on the front-lines.
Executive Leadership
Michelle Morand
Co-founder and Chief Executive Officer
As co-founder and CEO of both Liquid Biopsy Labs and CTOAM, Michelle Morand is passionate about helping patients, doctors, and researchers to access the best Next-Generation Sequencing tests available. With feedback from the Liquid Biopsy Labs Research Team, she develops company protocols that allow our clients’ needs to be met quickly and effectively. She also regularly communicates with industry peers and fellow innovators in Precision Cancer Medicine to bring together shared insights and move the field forward.
Michelle also holds more than 30 years experience as an entrepreneur and clinical counsellor. At the age of 25 she founded the CEDRIC Centre – an innovative treatment facility for eating disorders and other addictions and related concerns, such as anxiety, depression, trauma and the establishment of healthy relationships. She has dedicated her professional career to helping others and pioneering innovative approaches to create change on a foundational level and large scale.
With the support of the team at Liquid Biopsy Labs, Michelle is dedicated to helping patients get rapid access to these groundbreaking sequencing technologies and improved treatment outcomes. Michelle believes that everyone who receives a cancer diagnosis deserves to have access to personalized genetic testing and research – and to the best possible treatment for their cancer. She is committed to making that goal a reality.
Michelle Morand, MA, RCC
Co-founder and Chief Executive Officer
Contact Michelle
Executive Leadership
Alex Rolland
Co-founder and Chief Science Officer
Molecular Oncology Scientist and Precision Cancer Medicine Specialist, Alex Rolland, is co-founder and Chief Science Officer of Liquid Biopsy Labs. As Chief Science Officer, Alex develops groundbreaking NGS tests for cancer that better allow his team of personalized research specialists at CTOAM (Cancer Treatment Options and Management) to identify the most effective therapies and advocate directly for our clients.
He completed his PhD studies in Medical Genetics at the Terry Fox Laboratory in Vancouver (BC Cancer Agency), holds a BSc in Molecular/Cell Biology from the University of Victoria, and has over 30 years experience as a highly respected research scientist in cancer and oncogenomics. Alex is passionate about helping anyone who receives a cancer diagnosis has access to the most effective, and least invasive, form of NGS testing possible – as well as access to the optimal treatments for the molecular features of their cancer.
Alex has led multiple research studies at the University of Victoria and the University of British Columbia and also used his expertise to consult oncologists at the Mayo Clinic and other leading cancer treatment centers.
With over 15 years of experience developing leading-edge sequencing tests, researching, consulting, and advocating for cancer patients, Alex bridges the gap between the newest advancements in cancer diagnostics and patients and doctors on the frontlines.
Alex Rolland, BSc (Honours with distinction) Molecular/Cell Biology
Co-founder and Chief Science Officer
Management and Research Team
Dr. M. Abdalla, MSc, PhD
Vice President, Scientific and Regulatory Affairs
Dr. Abdalla is Vice President of Scientific and Regulatory Affairs at Liquid Biopsy Labs (LBL). He leads the scientific strategy, regulatory affairs, and quality systems supporting the development and clinical validation of the company’s advanced liquid biopsy and multi-omic molecular testing platforms.
Dr. Abdalla brings more than two decades of leadership experience in biotechnology, molecular tests, and clinical laboratory operations. His expertise spans precision oncology, assay development, regulatory strategy, laboratory governance, and the commercialization of innovative molecular technologies. Throughout his career, he has led the development of more than 100 molecular biology and in-vitro testing technologies and supported the regulatory authorization and global deployment of numerous diagnostic platforms.
He is widely recognized for his expertise in sample collection technologies and sample preparation workflows for complex biological specimens, including low-abundance nucleic acids and challenging matrices such as plasma, urine, saliva, and stool. His work has contributed to advancing molecular diagnostics capable of extracting clinically actionable signals from minimally invasive biological samples.
Dr. Abdalla has also overseen translational research programs, biomarker-driven clinical studies, and contract research collaborations, working with leading academic and clinical institutions to accelerate the development and validation of next-generation molecular diagnostic technologies.
At LBL, he directs the scientific development and regulatory strategy for the company’s blood-based Exosomal RNA assay, an innovative liquid biopsy platform designed to provide non-invasive insights into tumor biology, treatment response, and disease monitoring. He also leads the implementation of internationally recognized quality frameworks, including ISO 15189 and ISO 13485, supporting LBL’s mission to deliver clinically actionable molecular testing that advance precision oncology and improve patient outcomes.
Management and Research Team
Noushin Moshgabadi, MSc (Genetics), MSc (Medical Genetics)
Cancer Research Specialist
Research scientist Noushin Moshgabadi loves helping connect people with better healthcare and cancer treatment through her work in medical science.
Originally from Iran, Noushin has been living in British Columbia, Canada, for more than 15 years where she has studied and worked in scientific research for more than a decade. She obtained her Bachelors of Science in Cell & Molecular Biology from Vancouver’s Simon Fraser University (SFU); and her Masters of Science in Genetics, as well as her secondary Masters of Science, from the University of British Columbia’s Medical Genetics department (UBC).
Noushin has worked as a research scientist at Public Health Agency of Canada (PHAC), UBC hospitals, the Vancouver Prostate Centre (VPC), and several Genetics and Molecular Biology laboratories at both Simon Fraser University and the University of British Columbia.
With her deep passion for genetics, molecular biology, and scientific research, Noushin is excited to be a part of the Liquid Biopsy Labs team and working with cutting-edge experts who are leading the way in cancer care. Her life goal is to help people through medical science – and she feels that Liquid Biopsy Labs provides her with an opportunity to make this dream come true.
Management and Research Team
Dr. Alaknanda Dhotre, MD, MBA, RAQC, MA
Cancer Research Scientist and Regulatory Affairs Specialist
Dr. Alaknanda is a seasoned physician and researcher with over 16 years of experience in the fields of molecular bioscience, medicine, research and strategy in healthcare, pharma, medical devices, diagnostics, AI-ML applications, and regulatory affairs. She has worked with the USFDA, Health Canada, EMA, and Asian regulatory affairs and QMS.
She has completed her medical graduation (MD) from Seth G.S. Medical College and KEM Hospital, Mumbai; her Master’s in Family Medicine from Christian Medical College (CMC) Vellore; her MBA and clinical trial certification from Johns Hopkins University, Baltimore, USA; and post-graduation work in regulatory affairs and quality control from Seneca College, Ontario, Canada, with President’s Honors. She has also done MA in English Literature with distinction from Mumbai University. She is an accomplished academic and a recipient of multiple gold medals.
At Liquid Biopsy Labs, Dr. Alaknanda is responsible for supporting cancer genomic research at clinical and lab interface, research data analysis and report preparation, research publications, regulatory affairs and quality management system and business development.
She finds her role at Liquid Biopsy Labs intellectually rewarding, as it provides continuous learning opportunities through the exploration of genomics – where each of the 20,813 genes offers unique insights. Dr. Alaknanda is particularly intrigued by the cutting-edge RNA genomic platform, recognizing its significant potential not only in cancer molecular testing and therapeutics but also across a broad range of other medical applications.
Management and Research Team
Dr. Saima Paracha, MD
Molecular Specialist
Saima is a graduate of the Medical Sciences program from Dow University of Health Sciences in Pakistan. She has completed a post graduate diploma program in Public Health Data Analysis from University of Victoria and has worked as a Physician Assistant and Research Assistant in different specialties for several years.
Saima has seen many people in her life affected by cancer and is dedicated to helping others with cancer. She knows how effective Precision Cancer Medicine is and that it offers a way to eliminate cancer faster with reduced side-effects. Inspired by new medical technologies and advancements in medicine, Saima is proud and passionate about her with Liquid Biopsy Labs.
Get your questions answered live!
Join our drop-in Zoom sessions with our co-founder, Michelle Morand.